As of February 2026, CG Oncology has approximately $903.0 million in cash to fund operations into 2029. The company announced an expedited timeline for PIVOT-006 nearly a year ahead of schedule, which is the first Phase 3 randomized trial in intermediate-risk NMIBC encompassing the broadest range of patient types per AUA/SUO Guidelines. CG Oncology maintains a "Strong Buy" rating driven by significant pipeline progress and multiple upcoming catalysts in 2026.
Cyborg Score Rationale
The company has achieved a robust 24-month complete response rate of 41.8% with cretostimogene monotherapy and 75.5% complete response rate in BOND-003 Cohort C. With $903 million in cash sufficient to fund operations into the first half of 2029, the company has strong financial runway.
Top Insights
PIVOT-006 Phase 3 data expected in 1H 2026 nearly a year ahead of schedule, underscoring excitement for cretostimogene
BOND-003 Cohort P demonstrated high-grade event-free survival rates of 95.7%, 84.6%, and 80.4% at 3, 6, and 9-month follow-up
HC Wainwright raised price target from $75 to $80 with "buy" rating in February 2026
BLA submission completion expected in 2026 for initial indication of high-risk BCG-unresponsive NMIBC with CIS
Named Competitors
Valrubicin — First-line intravesical therapy for BCG-unresponsive high-risk NMIBC
Adstilidase Alfa (Adstiladrin) — Oncolytic immunotherapy for high-risk BCG-unresponsive NMIBC
Checkpoint inhibitor combinations — Pembrolizumab and nivolumab-based combinations in development for NMIBC
Recent Developments
(February 2026) Reported $903M cash position and updated financial results for 2025 with multiple upcoming catalysts
(January 2026) Announced accelerated PIVOT-006 Phase 3 timeline for intermediate-risk NMIBC data delivery
(December 2025) Presented positive late-breaking data at SUO meeting showing durable responses in multiple BOND-003 cohorts
(February 2026) HC Wainwright upgraded target price to $80 with continued "buy" rating
Open the full interactive CG Oncology, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.